Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
| Revenue (TTM) | $2.91B |
| Gross Profit (TTM) | $1.60B |
| EBITDA | $875.83M |
| Operating Margin | 17.10% |
| Return on Equity | 3.21% |
| Return on Assets | 2.37% |
| Revenue/Share (TTM) | $25.77 |
| Book Value | $64.78 |
| Price-to-Book | 2.19 |
| Price-to-Sales (TTM) | 5.79 |
| EV/Revenue | 6.24 |
| EV/EBITDA | 23.54 |
| Quarterly Earnings Growth (YoY) | 1.20% |
| Quarterly Revenue Growth (YoY) | 1.30% |
| Shares Outstanding | $111.59M |
| Float | $102.49M |
| % Insiders | 0.26% |
| % Institutions | 96.56% |
Volatility is currently expanding
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear. A critical public health challenge, T1D is often only identified after significant beta-cell damage has occurred, presenting first as a life-threatening diabetic k.
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RVTY and any ticker you trade — then tracks every position and per-strategy win rate.
